Innovative technologies from multiple research teams are reshaping cancer diagnostics and therapeutic monitoring. The University of Birmingham developed a urine test detecting bladder cancer via tumor DNA epigenetic changes using long-read sequencing. At Salk Institute and UC San Diego, boosting a unique heparan sulfate molecule shows potential to slow pancreatic cancer progression. Alchemab Therapeutics secured $32 million to advance neuroprotective antibody candidates in clinical trials. Meanwhile, new AI-driven models are predicting disease risk decades in advance, offering transformative predictive capabilities for oncology and other health fields.